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Abstract
The liposomes present great potential for applications in targeted delivery of chemo-
therapeutics in the treatment of cancer. The use of liposomal drug carriers as vehicles for 
targeting of chemotherapeutic agents to tumor tissues is based on their advantages over 
other dosage forms, represented by their low systemic toxicity, their bioavailability, and 
their possibility to enhance the solubility of different chemotherapeutic agents, due to the 
ability to encapsulate both hydrophilic and lipophilic drugs. They enhance the therapeu-
tic index of anticancer drugs by increasing the drug concentration in tumor cells through 
tumor targeting. The available approaches used for tumor targeting using liposomes are 
passive targeting, active targeting, and triggered drug release. The most advanced tar-
geting strategies proposed for cancer treatment are the development of multifunctional 
liposomes, having combined targeting mechanism. In this chapter, the tumor-targeting 
mechanisms are described in detail as well as the possibilities to design the targeted lipo-
somal nanocarrier in order to reach the desired target in the body and minimizing the 
off-target effects. Moreover, the current status of preclinical and clinical evaluation is 
highlighted.
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1. Introduction
The main characteristic of cancer is the existence of abnormal rapidly proliferating cells. 
Conventional chemotherapy is based on using chemotherapeutic agents that eliminate these 
uncontrollably dividing cells [1]. Most currently used anticancer agents are not able to differ-
entiate between cancerous cells and normal ones, resulting in high systemic toxicity and side 
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effects [2]. Because of the severity of the side effects, often dose reduction or cessation of the 
treatment is necessary, rendering chemotherapy inefficient [3]. By limiting the administered 
dose to reduce excessive toxicity, only a small fraction of the drug will reach the target tumor 
site, whereas the remaining portion of the drug will be distributed to other tissues in the 
body. This lack of specificity toward cancerous cells translates into an insufficient amount of 
chemotherapeutic drug reaching the site of action [1]. Liposomal nanosystems can overcome 
the drawbacks of conventional chemotherapy, by increased drug delivery in the tumor tissue 
and lower drug concentration in normal tissues. This way, the therapeutic efficiency of che-
motherapy is increased, while the toxicity and side effects are reduced [4]. Also, due to their 
small size, the circulation time of standard chemotherapeutic agents is often short as they 
are rapidly eliminated from the bloodstream by macrophages, thus reducing the effective 
drug concentration at the tumor site [3]. Moreover, the majority of current chemotherapeu-
tic agents have poor water solubility and absorption, which result in low bioavailability [2]. 
The incorporation of the chemotherapeutic drugs in liposomal drug delivery systems offers 
advantages by protecting the drug from degradation, increasing its circulation time in the 
bloodstream and overall improving its pharmacokinetic profile [1, 2].
2. Liposomal nanoformulations for tumor targeting
2.1. Liposomes for passive tumor accumulation
Passive targeting consists in the transport of nanocarriers through leaky tumor capillary 
endothelium into the tumor interstitial space [5]. The underlying mechanism, which makes 
passive targeting possible, is the enhanced permeability and retention (EPR) effect.
It was observed that certain circumstances, such as inflammation/hypoxia, tumors, or infarcts, 
can determine an enhanced permeability of the endothelial lining of the blood vessel wall com-
pared with the normal state of the tissue [6]. When reaching a given size, a tumor can no longer 
rely on the normal vasculature present in its vicinity to provide all the oxygen supply needed 
for its further proliferation. Therefore, as oxygen-deprived cells start to die, they secrete 
growth factors that promote the formation of new blood vessels from the surrounding capil-
laries, process known as angiogenesis [7]. These newly formed irregular blood vessels lack the 
basal membrane of normal vascular structures, thus presenting a discontinuous epithelium, 
which allows particles, such as nanocarriers (in the size range of 20–200 nm), to extravasate and 
accumulate inside the interstitial space [8]. Following permeation into the tumor, the enhanced 
accumulation of nanocarriers in the tumor microenvironment is favored by the poor lymphatic 
drainage in the tissue. In tumors, the lymphatic function is defective, resulting in minimal 
uptake of the interstitial fluid. Therefore, nanocarriers that have reached the perivascular space 
are not cleared efficiently and accumulate in the tumor interstitium [7]. This spontaneous accu-
mulation or “passive” targeting is currently known as the EPR effect [9]. Utilization of the EPR 
effect is therefore an effective strategy for targeting nanopreparations, such as liposomes, to the 
site of a tumor and has been extensively documented using various tumor types and animal 
models, since its early discovery in 1980s by Matsumura and Maeda [10, 11].
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Several factors have been shown to influence and favor the EPR, for example, prolonged 
systemic circulation that allows longer interaction of liposomes with the target, size of the 
liposomes, composition, and charge on the surface of liposomes [12]. Longevity in blood 
is achieved by coating the liposomes with polymers, such as polyethylene glycol (PEG). 
PEG has been shown to protect liposomes from recognition and rapid removal from the cir-
culation by the mononuclear phagocyte system (MPS), enabling the liposomes to stay in the 
circulation for a prolonged period of time and allowing them to substantially extravasate and 
accumulate in tumors, hence giving the liposomes long-circulating properties [13]. PEG pre-
vents opsonization by shielding of the surface charge, enhancing the repulsive interaction 
between polymer-coated liposomes and blood components, increasing surface hydrophilic-
ity, and forming a polymeric layer over the liposome surface which renders them imperme-
able to opsonins [14, 15]. Additionally, their accumulation in the tumor is strongly linked on 
the size of the endothelial gaps in the capillary vasculature, which varies between 200 and 
2000 nm, depending on the tumor type, its environment, and its localization [7]. An effective 
extravasation has been shown to occur for particles averaging from 30 to 100 nm in the case 
of hyperpermeable tumors such as murine colon adenocarcinoma, whereas for poorly perme-
able tumors (human pancreatic adenocarcinoma), only particles smaller than 70 nm proved 
to be effective [16, 17]. Last, the composition and charge on the surface of liposomes have 
impact on passive targeting. The presence of surface-charged lipids can alter the opsonization 
profile of the liposomes, their recognition by cells of the MPS, and hence their overall plasma 
circulation profile [18, 19]. While anionic or neutral liposomes escape from renal clearance, 
the positive surface charge of cationic liposomes leads to nonspecific interactions with the 
anionic species in the blood, resulting in rapid clearance from circulation by the reticuloen-
dothelial system (RES), which reduces the EPR effect [11, 12]. Moreover, it has been reported 
that the aggregation of liposomes occurs with greater amounts of cationic lipids in the liposo-
mal membrane; therefore, an optimization of the composition of the liposomal membrane is 
crucial for enhancing tumor penetration [20].
Conventional liposome formulation is based on the use of phospholipids and cholesterol, the 
last playing an essential role in the regulation of liposomal membrane fluidity, affecting ves-
icles permeability and stability [21]. Unmodified liposomes are rapidly eliminated from the 
circulation by the macrophages of RES, their main clearance sites being liver and spleen [22]. 
Grafting of PEG on the surface results in the formation of “stealth” or stabilized liposomes, 
which have improved in vivo stability and increased circulation time, up to 24–48 h (the long-
circulating liposomes). PEG performance as stabilizer depends on chain length, optimal sur-
face density, and optimal chain configuration. The percentage of PEGylated phospholipids 
necessary for stealth behavior is about 5–7% mol. with PEG 2 KDa and 15–25% with smaller 
PEG 350 Da to 1 kDa. Depending on the PEG density and configuration on the liposome struc-
ture, three models are possible: “mushroom” (low-polymer density), “pancake” (high-graft 
density), or “brush” (ideal model, ensuring efficient coverage of the surface) [11, 23].
It was reported that PEGylated egg phosphatidylcholine-cholesterol liposomes loaded with 
doxorubicin (DOX), having ~100 nm, passively accumulated in the tumor vessels of a multi-
drug-resistant breast cancer xenograft model, exhibiting a remarkable antitumor effect, where 
the free DOX failed to provide any detectable therapeutic effect [24].
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Mitoxantrone (MTO), an anthracenedione closely related to anthracyclines, was encapsulated 
in PEGylated liposomes, and efficacy studies in breast cancer model using liposomal-based 
MTO chemotherapeutic treatment in comparison with free MTO were realized. MTO encap-
sulation in liposomes limited the toxicity, which allowed the administration of higher MTO 
doses in the treatment of breast carcinoma on mice [25].
Recently, scientists reached the conclusion that the EPR effect is much more complex than 
initially defined, as it encompasses complex biological processes such as angiogenesis, vas-
cular permeability, hemodynamic regulation as well as heterogeneities in tumor genetic pro-
file and in the tumor microenvironment and lymphangiogenesis. As these factors differ from 
patient to patient and from one tumor type to another, they represent an important source of 
variability when considering the distribution and accumulation of liposomes in tumors. For 
these reasons, the sole use of the EPR effect as targeting mechanism may now be considered 
outdated, leaving the focus on designing actively targeted liposomes and liposomes, which 
combine the passive tumor accumulation with active targeting and/or stimuli sensitivity [2].
2.2. Actively targeted liposomal systems
The limitations of passive tumor targeting have been addressed by developing another kind 
of targeted drug delivery named active targeting. Various receptors are known to be involved 
in the development and progression of cancer, so they can be regarded as potential targets 
for the development of drug delivery systems. Liposomal drug delivery systems for active 
targeting are designed to have targeting moieties attached on their surface. The targeting 
ligands bind to the corresponding receptors or surface molecules which are overexpressed on 
the surface of the tumor cells or tumor vasculature [2, 26]. As a result, liposomes are internal-
ized in the tumor cells by endocytosis and drug concentration in tumor cells is increased [12]. 
The targeting moieties can be monoclonal antibodies, fragments of antibodies, peptides, pro-
teins, nucleic acids, carbohydrates, or small molecules [2, 26].
The design of liposomes for active targeting is a complex task in which various factors must 
be taken into account. For instance, the manufacturing material and the size of the liposomes, 
the type of ligand, the ligand conjugation method, and the ligand density determine the effi-
cacy of the liposomal system both in vitro and in vivo. The affinity of a ligand for its target is 
greatly affected by the density of the ligand on the surface of the liposomes [26]. Generally, 
an increased ligand density favors the uptake of the delivery system as there is a higher prob-
ability of interaction with the target (multivalency) [27]. However, a supplementary increase 
in ligand density can negatively impact on ligand-substrate interactions due to improper ori-
entation of the ligand, steric hindrance of vicinal molecules, and so on. To bind to its specific 
substrate, a ligand has to be in the proximity of its target, to be able to recognize and interact 
with it, so the design of liposomal systems with increased circulation time will favor the inter-
action [26]. As shown above, modifying the surface of the liposomes with PEG can prolong 
the blood circulation time by avoiding opsonization, but PEG with long chains can hinder 
the binding of the ligand to its target and PEGylation can increase the size of the liposomes. 
Besides PEGylation, the size of the liposomes and the surface and ligand charge have impor-
tant contributions in the ligand-substrate interactions. The size of the liposomes can influence 
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cellular uptake and intracellular deposition. The charge of the liposomes and the ligand can 
determine attractive or repulsive forces, which in turn will affect the degree of conjugation. 
This problem can be solved by adding a spacer, like PEG. It has been shown that cationic 
liposomes bind to their targets and are consequently internalized to a greater extent than 
negatively charged particles [26].
Generally, an active targeting liposomal drug delivery system consists of the following com-
ponents: (1) the liposomal carrier, (2) a hydrophilic polymer forming a protective layer around 
the liposome, (3) a ligand specifically targeting a certain substrate, (4) a linker molecule or a 
functional group that couples the ligand to the liposome, and (5) a drug encapsulated in or 
bound to the liposomal system. Ligands can be covalently or non-covalently bound to the 
surface of the liposome. The most extensively used approach is the one based on covalent 
binding of the ligand to the liposomes, usually done with the aid of a linker through a series 
of chemical reactions [28].
The ligand can be conjugated to the liposomes’ components (e.g., a lipid) either prior to 
liposome preparation or afterwards. Usually, a pre-liposome preparation conjugation has 
the advantage of allowing better control of the liposomes’ physicochemical properties. On 
the other hand, the post-liposome assembly strategy is based on coupling the ligand to the 
already-prepared liposomes, and is applied if the ligand changes the properties of the lipo-
somes’ components, the ligand is too large to participate in self-assembly, or has a poor stabil-
ity in organic solvents [26].
Active targeting can be addressed either to tumor cells or to the tumor endothelium.
2.2.1. Active targeting of tumor cells
In targeting tumor cells, the ligand should have a high affinity for a specific receptor over-
expressed by tumor cells in order to bind to the receptor and subsequently be endocytosed 
into the cells. The receptors most exploited in active targeting include the following discussed 
below [2].
The folate receptor is overexpressed in various types of cancer such as breast, ovarian, lung, 
colon, kidney, and brain cancers [29]. It has two isoforms: the alpha isoform, which is overex-
pressed in most cancers, and the beta isoform, which is expressed on the surface of activated 
macrophages [2]. Active drug delivery targeting the folate receptor involves conjugating folic 
acid to the surface of liposomes, usually through a PEG spacer between the lipids and the 
folate. Several liposomal systems conjugated with folic acid have been developed for the 
delivery of different anticancer agents, including imatinib [30], docetaxel [31], DOX [32], and 
daunorubicin [33]:
a. The transferrin receptor (TfR) is a transmembrane glycoprotein involved in cellular iron 
uptake from transferrin (Tf), a plasma protein, by receptor-mediated endocytosis [34]. The 
TfR has been explored as a target for cancer treatment due to its accessibility, its pivotal role 
in cell growth, and proliferation and also its overexpression by various types of malignant 
cells [35]. Recently, nanoparticulate systems modified with Tf were proposed to  deliver the 
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chemotherapeutic agents across the blood-brain barrier (BBB), for the treatment of brain tu-
mors such as glioma. For instance, Tf was attached to the surface of vincristine and tetran-
drine-loaded liposomes [36] and for modifying liposomes loaded with cisplatin [37]. Both 
liposomal formulations showed a more potent cytotoxic effect on tumor cells than the free 
drugs and the non-modified liposomal drugs, on C6 glioma cells in vitro [36, 37].
b. The epidermal growth factor receptor (EGFR) is a 170-kD glycoprotein which belongs to 
the ErbB family of tyrosine kinase receptors. The EGFR plays a crucial role in cancer pro-
gression and metastasis since it activates signaling pathways responsible for promoting cell 
proliferation, angiogenesis, and inhibiting apoptosis [38]. Overexpression of EGFR has been 
observed in various types of cancer, including breast, lung, colon, ovarian, pancreatic, and 
kidney cancers [2]. EGFR-mediated delivery via liposomes is based on using antibodies or 
antibody fragments embedded in the lipidic membrane. Several anti-EGFR-liposomal sys-
tems have been reported for the delivery of DOX [39, 40]. A work describes the development 
of a large-scale, Good Manufacturing Practice (GMP) compliant process for manufacturing 
EGFR-targeted immunoliposomes loaded with DOX, using the already approved Cetuxi-
mab (C225) and PEGylated-liposomal DOX (Caelyx®). The liposomal formulation was safe, 
according to the results of a clinical trial [41]. Cetuximab or Cetuximab fragments (Fab’) 
were also coupled to oxaliplatin-loaded liposomes for increased selectivity for tumor cells. 
Both liposomal formulations showed greater cellular uptake than untargeted liposomes in 
EGFR-positive cell cultures in vitro, and in vivo experiments on colon cancer-bearing mice in-
dicated improved efficacy over untargeted liposomal oxaliplatin. Liposomes equipped with 
Fab’ fragments bound to a higher extent to EGFR and had better uptake than liposomes 
coupled to Cetuximab [42].
c. Glycoproteins expressed on the surface of cancer cells can be bound by lectins which can 
be used as targeting moieties on liposomes, since the bond between the two is very specific.
A PEGylated-liposomal system functionalized with recombinant human E-selectin for 
the selective delivery of DOX to tumor cells was designed by attaching E-selectin to the 
PEG chains of PEG2000-DSPE through a maleimide group. When tested on two circulat-
ing malignant cell lines expressing sialylated carbohydrate groups, a significant reduction 
in cell viability was obtained compared to the control and empty E-selectin-coupled lipo-
somes, which shows that the developed liposomal system could be useful in capturing and 
eliminating circulating tumor cells under flow conditions [43].
d. CD44 (cluster of differentiation 44) is a transmembrane glycoprotein which contains a 
specific binding domain for hyaluronic acid. CD44 is involved in a series of biological 
processes, including proliferation, migration, growth, differentiation, and angiogenesis 
[44]. Various cancers, such as leukemia, ovarian, colon, gastric, pancreatic, and epithelial 
cancers, have been documented to overexpress CD44.
Several liposomal systems decorated with hyaluronic acid have been described in  literature 
for the delivery of gemcitabine [45] and DOX [46] to tumor cells. Other reported methods 
of targeting the CD44 receptor involve using anti-CD44 monoclonal antibodies [44] or 
RNA aptamers (e.g., Apt1) [47].
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2.2.2. Active targeting of the tumor endothelium
This type of nanosystem is capable of binding and destroying tumor vasculature and indi-
rectly limiting the growth of the tumor cells that are supplied with nutrients and oxygen by 
these blood vessels. Targeting the tumor endothelium is advantageous because the nanosys-
tems do not have to extravasate in order to reach their site of action, and can directly bind to 
the corresponding receptors which are easily accessible [2]; the risk of developing resistance 
to chemotherapy is reduced because endothelial cells have less genetic variations than tumor 
cells, and markers expressed by endothelial cells are not specific for any type of tumor [12]. 
The main targets of the neovascular endothelial cancer cells are described below:
a. The vascular endothelial growth factor (VEGF) is produced by tumor cells in hypoxic con-
ditions [2]. VEGF and its receptor (VEGFR) play an important role in angiogenesis, induc-
ing the proliferation, migration, and survival of epithelial cells. Also, VEGF increases the 
permeability of blood vessels [48]. There are two main strategies of targeting VEGF-medi-
ated angiogenesis, namely targeting VEGFR to reduce VEGF binding or targeting VEGF 
to decrease its binding to VEGFR [2]. A novel PEGylated-liposomal system functionalized 
with a fully human anti-VEGF 165 monoclonal antibody was proposed for paclitaxel. The 
PEGylated immunoliposomes showed superior antitumor activity compared to unmodi-
fied liposomes and the commercially available paclitaxel (Taxol®) in SGC-7901 human gas-
tric cancer-bearing nude mice [48].
b. The integrins are a family of heterodimeric transmembrane glycoproteins participating in 
interactions between cells or between cells and extracellular matrix. They are composed 
of non-covalently bound polypeptide α- and β-subunits [12]. Among these integrins, 
α
v
β
3
-integrin seems to be the most important integrin in angiogenesis. It is an endothelial 
cell receptor for extracellular matrix proteins, including fibrinogen/fibrin, fibronectin, vit-
ronectin, thrombospondin, and osteopontin. Higher expression of α
v
β
3
-integrin has been 
observed in melanoma, lung, and brain cancers [2, 49]. Research has revealed that the 
arginine-glycine-aspartic acid (RGD) amino acid sequence is the binding site contained in 
all ligands bound by α
v
β
3
-integrin, and new RGD-containing peptides or derivatives with 
high affinity and selectivity for α
v
β
3
-integrin have recently been proposed. Moreover, the 
incorporation of cytotoxic drugs in nanosystems decorated with RGD-containing ligands 
could promote antitumor effect by offering a dual-targeting strategy against tumors [50].
A liposomal system containing DOX was engrafted with three different cyclo-RGD-based 
peptides: cRGDyC (Arg-Gly-Asp-D-Tyr-Cys), cRGDfK (Arg-Gly-Asp-D-Phe-Lys), and cRGDf[N-
Met]K (Arg-Gly-Asp-D-Phe-[N-Methyl]Lys). The latter peptide was synthesized based on 
Cilengitide, the most selective inhibitor of α
v
β
3
-integrin currently evaluated in a phase III 
clinical trial for glioblastoma therapy. In vitro experiments regarding liposome-cell associa-
tion and cytotoxicity were conducted in human umbilical vein endothelial cells (HUVEC) 
and emphasized the ability of RGD-targeted liposomes to associate to HUVEC through inte-
grin-mediated endocytosis. The therapeutic efficacy of RGD-targeted liposomes was assessed 
in C-26 colon carcinoma tumor xenograft model in mice. Among the investigated peptides, 
RGDf[N-Met]K had the most potent cytotoxic effect and increased the survival of mice [50]. 
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In another study, other three RGD-based peptides were evaluated as potential ligands, cou-
pled to liposomes: a monomeric c(RGDfK) (moRGD), a dimeric c(RGDfK) (diRGD), and a spe-
cial dimeric c(RGDfK) (P-diRGD) containing a PEG spacer between two cyclic RGD motifs. 
P-diRGD-modified liposomes exhibited the strongest interaction with and internalization in 
B16 murine melanoma cells. The targetability of P-diRGD-modified liposomes in B16-bearing 
mice was approximately 2.4-fold and 2.8-fold more increased than that of moRGD- and 
diRGD-modified liposomes [49].
2.3. Stimuli-sensitive liposomes
Stimuli-responsive liposomes have been developed with the purpose of overcoming prob-
lems associated with conventional and long-circulating liposomes, such as a slow release of 
the loaded drug or the incapacity to fuse with the endosome after internalization. The concept 
of increasing drug targeting through triggered release is based on utilizing subtle pathologi-
cal changes in the tumor microenvironment and has been extensively studied in the past years 
for improved efficiency of liposomal drug release [12, 51]. The stimuli-sensitive nanocarriers 
maintain their stealth function throughout circulation, and upon arrival at the specific tumor 
site, undergo rapid changes, such as aggregation, disruption, and permeability changes, 
which trigger drug release when exposed to a particular tumor microenvironment [2, 52, 53]. 
In order to achieve site-specific triggered drug release, several strategies have been investi-
gated, for example, internal stimuli that are characteristic for a tumor microenvironment (low 
pH, redox potential, high temperature, and enzymes) and external stimuli, such as magnetic 
fields, ultrasound, or light [54–56]. Both internal and external stimuli-sensitive liposomes will 
be addressed further, classified according to the mechanism exploited.
2.3.1. Internal stimuli
a. The pH-sensitive triggered release is based on the degradation of the liposomal carriers 
followed by the release of the entrapped drug in tissues with a low pH, such as tumors, the 
cell cytoplasm, or the endosome [2, 12]. Although PEGylation increases the longevity of the 
liposomes in the circulation, in some cases it does not guarantee the escape of liposomes 
from endosomes, allowing the degradation of their contents prior to achieving their target. 
With the purpose of overcoming this problem, pH-labile linkers have been introduced 
between the hydrophilic PEG and the hydrophobic moiety, linkers that are cleaved upon 
exposure to the relatively low-endosomal pH or the acidotic tumor mass [57].
pH-sensitive dextran liposomes having 3-methylglutarylated residues (MGlu-Dex) were 
described. Surface modification of phosphatidylcholine liposomes with MGlu-Dex enabled 
obtaining highly pH-sensitive liposomes that were stable at neutral pH but were strongly 
destabilized in the weakly acidic pH region (pH ~5.5). In vivo data suggested that com-
pared to unmodified liposomes, MGlu-Dex-ovalbumin liposomes efficiently increased the 
uptake of ovalbumin by dendritic cells and significantly suppressed tumor growth [58].
b. Temperature-triggered drug delivery represents an attractive strategy in cancer therapy, 
because compared to normal tissues, pathological areas, such as tumors, show a distinctive 
hyperthermia [2]. Temperature-sensitive liposomes release the encapsulated drugs at the 
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melting-phase transition temperature (Tm) of the lipid bilayer/the lower critical solution 
temperature (polymers), temperature at which the membrane changes its permeability, 
disrupting to release the drug [59]. Temperature-sensitive liposomes have been widely in-
vestigated in the last decades and successfully applied in both preclinical and clinical stud-
ies in combination with heat-based therapies, such as radiofrequency ablation, ultrasound 
hyperthermia, and microwave hyperthermia [60]. A temperature-triggered liposomal sys-
tem, ThermoDox® developed by Celsion Corporation (NJ, USA), has successfully demon-
strated its improved efficacy during phase III clinical trials for the treatment of hepatocel-
lular carcinoma and phase II trials for breast cancer and colorectal liver metastases [60].
c. Enzymes, such as matrix metalloproteinases—MMPs (e.g. MMP2), phospholipase A2, al-
kaline phosphatase, transglutaminase, or phosphatidylinositol-specific phospholipase C, 
are overexpressed in tumor tissues and have been suggested as potential candidates for 
enzymatically triggered drug release from liposomes [61]. A hybrid liposome composed of 
phospholipid (DPPC) and PEGylated block-copolymer (Poloxamer 188) was described for 
the rapid release of encapsulated DOX in the presence of phospholipase A2 (PLA2). Drug 
release from liposomes was facilitated by higher PLA2 concentrations and was found to 
be dependent on the temperature and the presence of calcium ion, partially explaining 
PLA2-responsive drug release. DOX release from liposomes triggered by PLA2 exhibited 
enhanced cytotoxic effects on the A549 lung cancer cell line, suggesting that DPPC/P188 
liposomes are a promising drug carrier for PLA2-expressing sites such as inflammatory 
lung cancer [62].
To overcome the fact that conventional liposomes have no mechanism for specifically releas-
ing the encapsulated cargos inside the cancer cells, calcein-loaded liposomes containing a 
novel destabilization peptide (LMDP) were proposed. This peptide can destabilize liposomal 
membranes upon cleavage by the intramembranous proteases in cancer cells. In vitro tests 
showed that encapsulated calcein was successfully released in the presence of a membrane 
fraction containing an LMDP-cleavable protease, proving the responsiveness of the system to 
the cancer-specific protease [63].
2.3.2. External stimuli
a. The use of activated light, made by the adjustment of parameters such as wavelength, inten-
sity, pulse duration, and cycle, has been recognized as a promising tool for several biomedi-
cal applications, including light-triggered drug delivery [12]. Visible light, UV, and near-
infrared (NIR) light have been investigated so far as triggers for the drug delivery; however, 
near-infrared is the most desirable for tumor targeting, since it penetrates deeper into the 
tissue. Thus, the preparation of porphyrin-phospholipid (PoP)-doped liposomes that are 
permeabilized by directly near-infrared light was described. Upon systemic administration, 
laser irradiation-enhanced deposition of actively loaded DOX in mouse xenografts, enabling 
an effective single-treatment antitumor therapy [64]. Another study reported the incorpora-
tion of an unsaturated phospholipid, such as dioleoylphosphatidylcholine (DOPC), in or-
der to accelerate the near-infrared light-triggered DOX  release in porphyrin–phospholipid 
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 liposomes. The formulation inhibited human pancreatic xenograft growth in mice following 
a single intravenous administration of 6 mg kg−1 DOX, loaded in liposomes [65].
b. Ultrasound-mediated drug delivery represents an attractive way to achieve noninva-
sive penetration into deep tissues and produce focused, controlled drug delivery [66]. 
 High-intensity focused ultrasound (HIFU) produces local heating, which can promote 
phase transition of the lipids, facilitating drug release from liposomes. While HIFU is con-
sidered ideal for deeper tumors, low-frequency ultrasound (LFUS) is only appropriate 
for superficial tumors and has been used to trigger drug release from stealth liposomes 
without affecting the physicochemical properties of the drug [67]. Moreover, it was dem-
onstrated that tumor vascular endothelium becomes more permeable after ultrasound.
A novel nanocarrier of emulsion liposomes (eLiposomes) composed of a perfluoropen-
tane nanodroplet within the aqueous interior of a DPPC liposome, along with the antican-
cer drug DOX, was described. In vitro studies showed that the liposomes displayed good 
release of DOX upon the application of low-intensity ultrasound at 20 kHz, 1.0 MHz, and 
3.0 MHz. This novel drug delivery system promises to provide enhanced drug delivery of 
DOX compared to traditional stealth liposomes and has the potential to reduce the side 
effects of cardiotoxicity caused by DOX [68].
c. Magnetic-triggered drug release has received great attention in the past years, as magnet-
ized liposomes have significant biomedical applications such as magnetic hyperthermia, 
magnetic transfection, and manipulation of cells and proteins [12]. Liposomes are usually 
magnetized by the incorporation of Fe
3
O
4
 or γ-Fe
2
O
3
, and once exposed to a magnetic 
field, the chemotherapeutic agent incorporated is completely released. Due to their mag-
netic properties, nanoscale size (approximately 10 nm), and biocompatible nature, these 
magnetized liposomes are also referred to as SPIONs [2]. For example, DOX-loaded mag-
netic liposomes were proposed as strategy for anti-colorectal cancer treatment, using a 
combination of chemotherapy and thermotherapy. In vitro cytotoxicity and hyperthermia 
studies were evaluated against colorectal cancer (CT-26 cells) with high-frequency mag-
netic field (HFMF) exposure and was found that the combination between DOX-loaded 
liposomes and HFMF was more effective than either hyperthermia or chemotherapy treat-
ment individually [69].
2.4. Multifunctional liposomes
The current trend reflected by the scientific publications in the field is to develop liposomal 
nanoformulations that simultaneously demonstrate more than one useful function, that is, mul-
tifunctional liposomes, by combining two (longevity and targetability; targetability and stimuli 
sensitivity) or even all three functionalities mentioned above (longevity, targetability, and stim-
uli sensitivity). Thus, an ideal nanoformulation used for tumor-targeting purposes should pos-
sess the following properties: long circulation in the body, specificity for the site of the disease, 
sensitivity to local/external stimuli found in/applied to the tumor tissue, enhanced intracellular 
delivery of the drug, contrast properties to allow in vivo visualization, and others [70].
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2.4.1. Liposomes combining in vivo longevity and specific target recognition
This type of liposomal formulations combine the drug delivery advantages of PEGylation, 
such as longevity in blood and passive tumor accumulation, with tumor cell-specific or tumor 
endothelium-specific delivery by ligand association at their surface. In spite of the advantages, 
the specific ligands attached to the surface of liposomes may increase the rate of uptake by the 
RES, could facilitate the development of unwanted immune response, and their amount must 
be optimized to ensure successful binding to the target [70].
The majority of research in this field utilizes monoclonal antibodies for the design of 
PEGylated immunoliposomes. Several PEGylated immunoliposomes designed for specific 
target of EGFR are described in Section 2.2.1. Others are designed to target the human epi-
dermal growth factor receptor 2 (HER2), a growth hormone receptor overexpressed on the 
surface of certain types of breast cancer cells. HER2 antibody was used in a recent study as 
a targeting ligand in PEGylated immunoliposomes loaded with DOX. The formulation was 
tested for combination therapy in association with liposomal bevacizumab, and animal stud-
ies revealed increased accumulation of DOX at the tumor site and a significant delay of tumor 
growth in the combinational liposomal drug delivery group compared to free DOX, liposo-
mal DOX, immunoliposomal DOX, and liposomal bevacizumab [71].
Several research groups developed long-circulating targeted liposomes as a strategy to trans-
port drugs across the BBB for treating brain glioma. Thus, polyethyleneimine (PEI), a posi-
tively charged polymer, and vapreotide (VAP), a synthetic somatostatin analog, were used as 
targeting molecules for vinorebline and tetrandrine. The multifunctional drug-loaded system 
demonstrated enhanced antitumor efficacy on glioma-bearing mice, explained by a combina-
tion of long circulation time in the blood (PEGylated lipids), enhanced transport of drugs 
across BBB (absorptive-mediated endocytosis by PEI, blocking the expression of P-gp pro-
tein by tetrandrine), and increased intracellular uptake by glioma cells and glioma stem cells 
(receptor-mediated endocytosis by VAP) [72].
Another group reported the use of stabilized peptide ligands, that is, cA7R (cyclic A7R) 
and DA7R, for multifunctional glioma-targeted drug delivery. The mentioned peptides 
were developed to enhance the proteolytic stability of the linear L-peptide A7R (LA7R), 
which binds with high affinity and specificity to vascular endothelial growth factor recep-
tor 2 (VEGFR2) and neuropilin-1 (NRP-1), which are overexpressed in glioma. In one 
study, DA7R, the retro-inverso derivative of LA7R, was associated to PEGylated liposomes 
to achieve multifunctional targeting of DOX to glioma. DA7R had similar binding affinity 
to its receptors in vitro, but DA7R-conjugated liposomes were superior to LA7R-modified 
liposomes in terms of antitumor efficiency in vivo, due to their better serum stability and 
higher tumor accumulation [73]. The same authors conjugated the cyclic derivative, cA7R, 
on the surface of DOX-loaded PEGylated liposomes, and the resulted system exhibited 
excellent antitumor, anti-angiogenesis, and anti-vasculogenic mimicry effects, resulting 
in improved therapeutic efficacy in U87 xenograft nude mice as compared to other DOX 
formulations (solution, non-functionalized liposomes, or liposomes functionalized with 
LA7R) [74].
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2.4.2. Active-targeted, stimuli-sensitive long-circulating liposomes
Many liposomal systems described combine long circulation properties, with active target-
ing and stimuli-responsive drug release functions. The release of drugs from such carriers is 
triggered specifically at target sites either by local characteristics specific for the tumor tissue 
or by the application of stimuli at target tissue from outside of the body [75]. Such multifunc-
tional approach was exploited in EGFR-targeting-thermosensitive liposomes. The liposomes 
were functionalized with GE11, an EGFR-specific peptide or Cetuximab antibody fragments 
(Fab’) for comparison, and dipalmitoylphosphatidylcholine (DPPC):DSPC:DSPE-PEG:DSPE-
PEG-GE11 were used to achieve thermosensitivity. The proposed liposomal formulation 
released DOX at temperatures above 40°C. Of the two investigated anti-EGFR ligands, Fab’ 
was more potent in terms of cellular uptake. On breast cancer cell lines, targeted liposomes 
encapsulating DOX proved to be more cytotoxic than the plain liposomal DOX [76]. In another 
study, multifunctional liposomes with target specificity, temperature-triggered drug release, 
and near-infrared fluorescence imaging were designed. DOX-loaded stealth liposomes were 
modified with thermosensitive poly[2-(2-ethoxy)ethoxyethyl vinyl ether] chains, conjugated 
with the antibody trastuzumab (Herceptin, HER), and furthermore indocyanine green was 
incorporated for near-infrared fluorescence imaging. The group reported the excellent ability 
of these liposomes for association and internalization to target cells overexpressing Her-2, 
when heated at 45°C for 5 min [77].
2.4.3. Multifunctional liposomes for enhanced intracellular delivery
In order to improve the cytotoxicity of the chemotherapeutics loaded in liposomes, the use 
of cell-penetrating peptides (CPPs), which enhance the transport through the plasma mem-
brane into cells, has been proposed [78]. Among these, the use of transactivator of transcrip-
tion peptide (TATp) in the design of multifunctional liposomes has been shown to enhance 
cell uptake and cytotoxicity of the loaded drug, or even to increase the therapeutic efficacy 
against multidrug-resistant cancer cells [79, 80]. To prevent the proteolytic degradation of 
TAT, which might alter its targeting properties, it is necessary to shield it, usually through the 
use of PEG chains.
In a recent study, the advantages of formulating paclitaxel (PTX)-loaded liposomes function-
alized with TAT and cleavable PEG via a redox-responsive disulfide linker (PTX-C-TAT-LP) 
were investigated. At tumor site, in the presence of exogenous reducing agent glutathione 
(GSH), PEG was detached and TAT was exposed to facilitate cell internalization. Compared 
to conventional stealth PTX-TAT liposomes, PTX-C-TAT-LP achieved enhanced tumor distri-
bution and demonstrated superior delivery efficiency both in vitro and in vivo [81]. Another 
study reports a novel dual-functional liposome system possessing mitochondrial target-
ing properties and extracellular pH response which has been proved to enhance paclitaxel 
accumulation into the mitochondria. Peptide D[KLAKLAK]2 (KLA) was modified with 2, 
3-dimethylmaleic anhydride (DMA) and combined with 1, 2-distearoyl-sn-glycero-3-phos-
phoethanolamine (DSPE) to yield a DSPE-KLA-DMA (DKD) lipid, which, at tumor extracel-
lular pH (~6.8), reversed the surface charge of liposomes (negative to positive), facilitating 
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their internalization. In vitro studies proved that pH-sensitive-modified liposomes exhibited 
improved efficacy in treating drug-resistant lung cancer A549/Taxol cells compared to con-
ventional therapy [82].
3. Clinical experience with liposomes for cancer chemotherapy
Research on chemotherapy via liposomal drug delivery has known significant progress in 
the last decades, evolving from in vitro and in vivo preclinical studies on animals to numer-
ous clinical trials. There are over 1000 clinical trials containing the terms “liposome” and 
“cancer,” either completed or active, according to The National Institutes of Health’s (NIH) 
web-based database, ClinicalTrials.gov and the EU Clinical Trial Register. There are sev-
eral ongoing clinical trials investigating the efficiency of liposomal cisplatin, NDDP (cispla-
tin analog), paclitaxel, mitoxantrone, irinotecan, SN38 (the active metabolite of irinotecan), 
topotecan, lurtotecan, a camptothecin analog, vinorelbine, annamycin, docetaxel, DOX, and 
vincristine [83–87]. The association of chemotherapeutic drugs is a frequently used strategy 
in chemotherapy. In this sense, some clinical trials evaluate the synergistic cytotoxicity of 
a combination of two agents, such as irinotecan hydrochloride-floxuridine and cytarabine-
daunorubicin in liposomal forms [86, 88].
Moreover, liposomes are the first nanoscale systems to be approved in 1995. The first liposo-
mal system approved by the regulatory authorities for the treatment of cancer was liposomal 
DOX (in 1995), marketed as Doxil® in the USA and Caelyx® in Europe [89, 90]. Other liposo-
mal DOX formulations, such as Myocet® and Lipo-Dox®, have also been introduced into the 
market [91]. Lipo-Dox®, Doxil®, and Caelyx® are sterically stabilized liposomal DOX formu-
lation having the same clinical indications. In contrast to these products, Myocet® is a non-
PEGylated liposome encapsulating DOX, used to treat metastatic breast cancer in association 
with cyclophosphamide [90].
Other cytotoxic drugs incorporated in approved liposomal products are daunorubicin and 
vincristine in DaunoXome® and Marqibo®, respectively [91]. DaunoXome® is a conven-
tional liposomal formulation containing daunorubicin as a citrate salt, used in clinical 
practice in the treatment of Kaposi’s sarcoma [91]. Marqibo® is a sphingomyelin and cho-
lesterol-based liposomal formulation of vincristine [90], indicated in acute lymphoblastic 
leukemia [91].
All aforementioned products are administered intravenously, but other routes of admin-
istration are also exploited in liposomal drug delivery. For instance, DepoCyt®, a lipo-
somal system containing cytosine arabinoside (a nucleoside analog of deoxycytidine), is 
administered spinally/intrathecally in neoplastic meningitis and lymphomatous menin-
gitis [92, 93].
Currently, there are several liposomal systems for active targeting that are being investi-
gated in different stages of clinical trials, but no formulation is commercially available. Most 
of them refer to liposomal systems modified with a transferrin receptor-targeted ligand. 
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For instance, MBP-426 is a liposome system conjugated with human transferrin for the deliv-
ery of  oxaliplatin in patients with advanced or metastatic solid tumors that has completed a 
phase I clinical trial. It was also investigated in a phase Ib/II clinical trial in combination with 
leucovorin and 5-fluorouracil in second-line patients with metastatic gastric, gastroesopha-
geal junction, or esophageal adenocarcinoma [94, 95].
Even though liposomes and targeting antibodies are both approved for clinical use, there 
are few studies on nanosystems which combine these two strategies. For example, anti-
EGFR immunoliposomes encapsulating DOX have been shown to target the epidermal 
growth factor receptor by coupling Fab′ fragments of the Cetuximab monoclonal antibody 
on the surface of the liposomes [96, 97]. MCC-465 is a PEGylated immunoliposome con-
taining DOX, modified with the F(ab')2 fragment of GAH human monoclonal antibody, 
for the treatment of gastric cancer [97, 98]. The delivery of DOX to the brain via liposomes 
has been enhanced by conjugation with glutathione. 2B3-101 is a glutathione-PEGylated-
liposomal system capable of transporting DOX across the BBB by using the glutathione 
transporters [97, 99].
4. Conclusions
The liposomes present great potential for applications in targeted delivery of chemothera-
peutics in the treatment of cancer. Based on their potential, several formulations are already 
approved and are clinically used in cancer treatment. However, many more have failed dur-
ing the preclinical evaluation or early stages of clinical development. Therefore, future devel-
opment of liposomal-based-targeted chemotherapy should comprise strategies based on deep 
understanding of the pathophysiological mechanism of the disease, on the preparation pro-
cess and stability issues, and on the correlation between the physicochemical characteristics 
of the nanocarrier and its targeting ability.
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